Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
looking good so far
under 1,000,000 float, but less than $200 cash i think, got to get in and out fast if this one starts moving
strange, someone is buying up every ask slowly
sold at 3.44, 7 minute trade, might get back in under 2.50, other than that not sure i want to gamble here again
small order at 2.35, want to see the bids over 3.00
still watching for a spot to possibly enter.
tried to get at 2.00 a little bit ago, missed out on 2nd run up.
yeah, i pulled my bid just in time, still watching for possible gamble
looking like everyone who has shares is probably dumping
OTC says there are only 25,255 shares held at DTC?
what do you think about MICR?
anybody understand the 1.50 a share?
to bad someone has the sell button on speed dial, every bid getting dumped into it looks like
Outstanding Shares 19,261,770 - 04/14/2023
OTC warrning:
Warning! This security is eligible for Unsolicited Quotes Only
This stock is not eligible for proprietary broker-dealer quotations. All quotes in this stock reflect unsolicited customer orders. Unsolicited-Only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.
you own more than 219,000 shares, and you say it's a 4 million float, so you own at least 5 percent of the float?
how do you think they're going to pay for everything?
As of November 30, 2022, we had $21,600 in cash compared to $786,414 on November 30, 2021. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.
We had no cash flow from investing activities during the three months ended November 30, 2022, compared to $513 cash flow from investing activities for the three months ended November 30, 2021.
We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.
Borrow money from shareholders, 900,000,000 authorized shares, Israel.
The Company is authorized to issue up to 900,000,000 shares of common stock, par value $0.0001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.
As of November 30, 2022, the Company had 5 employees, two of which were our Directors Gabriel Yariv and Eyal Barad, which along with our counsel and CFO were given monthly salaries. Aside from counsel, all employees reside in Israel.
As of November 30, 2022, we had $21,600 in cash compared to $786,414 on November 30, 2021. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.
We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.
they hit you hard on these boards when you mention dilution
as of January 10th, only 1,257,927 shares were outstanding, public float 492,340, 900,000,000 shares authorized
We used cash in operations of $95,915 for the three months ended November 30, 2022, compared to cash used in operations of $599,545 for the three months ended November 30, 2021. The negative cash flow from operating activities for the three months ended November 30, 2022, is primarily attributable to the Company's net loss of $357,699, an increase in accounts payables and accrued liabilities of $2,687 and a decrease of $135,784 in account receivables and prepaid expenses, depreciation of $43,185, convertible loan valuation of $4,542 and share-based payment of $75,557
We had no cash flow from investing activities during the three months ended November 30, 2022, compared to $513 cash flow from investing activities for the three months ended November 30, 2021.
We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.
Borrow money from shareholders, 900,000,000 authorized shares, Israel.
The Company is authorized to issue up to 900,000,000 shares of common stock, par value $0.0001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.
As of November 30, 2022, the Company had 5 employees, two of which were our Directors Gabriel Yariv and Eyal Barad, which along with our counsel and CFO were given monthly salaries. Aside from counsel, all employees reside in Israel.
As of November 30, 2022, we had $21,600 in cash compared to $786,414 on November 30, 2021. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.
We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.
that's what it's looking like, OTC site says security details are "not available", might just be a glitch today because it's doing the same for others, but not all. but i'm sure they're still diluting, will never know when they turn the faucet off
they only have $67.43 cash? bet they'll have a lot more after today.
OUCH, 75 million to 950 million
The Arax Board of Directors (“Board”) is furnishing this Information Statement to inform stockholders as of December 20, 2022 (“Record Date”) that, on December 19, 2022, a stockholder of voting shares representing 90.63% of the voting power of the total issued and outstanding voting shares of the Company (“Majority Stockholder”) authorized by written consent (“Written Consent”) an amendment to the Company’s Certificate of Incorporation increasing the number of authorized shares of common stock, par value $0.001, (“Common Stock”) from 75,000,000 to 950,000,000. The Board unanimously approved the amendment (“Amendment”).
With hardly any volume, this may just go on for a very long time. Who knows what it was from December, 2022.
As of December 31, 2021, the Company has an accumulated deficit of $57,823,102, total stockholders’ deficit of $8,372,175, negative working capital of $8,270,892 and cash and cash equivalents of $773,423.
more dilution, i have a feeling this won't stop for a very long time
Outstanding Shares
18,135,606
03/17/2023
seems a pump might be coming, unless it's already over.
what happened yesterday, more volume than the last year alone it seems
even if it's the bottom, i don't think it's going anywhere anytime soon. just like 99 percent of the other OTC's they will just continue selling shares and diluting.
still no dilution?
Outstanding Shares
14,493,814
03/01/2023
Outstanding Shares
14,493,814
03/01/2023
1.1 billion shares authorized. The Company has incurred significant losses since inception, incurred a loss of $3,371,137 for the nine months ended September 30, 2022, and, as of September 30, 2022, the Company has an accumulated deficit of $61,194,239, total stockholders’ deficit of $11,350,562, negative working capital of $11,394,916 and cash of $151,557.
Not saying people won't make money here, but i smell dilution, they need money, good luck.
they'll be back, they've got millions to dump
someone knew something on January 13th.
company is authorized to sell 1.1 billion shares i believe?
Outstanding yes, authorized up to a billion. So around 879 million more to go
The aggregate number of shares, which the corporation shall have authority to issue, shall consist of 1,000,000,000 (one billion) shares of Common Stock, having a $0.001 par value per share, and 100,000,000 shares of Preferred Stock, each having a $0.001 par value per share. The Common and/or Preferred Stock of the Company may be issued from time to time without prior approval by the stockholders. The Common and/or Preferred Stock may be issued for such consideration as may be fixed from time to time by the Board of Directors. The Board of Directors may issue such share of Common and/or Preferred Stock in one or more series, with such voting powers, designations, preferences and rights or qualifications, limitations or restrictions thereof as shall be stated in the resolution or resolutions.
going to need some "whales" to buy up those billion shares, LMAO
and going to close red
should there have been an 8-K filed regarding the contract, or at least by tomorrow?
i think it's the Sykes crew dismantling this